Loading...

9 Meters Biopharma, Inc.

NMTRNASDAQ
Healthcare
Biotechnology
$0.07
$-0.05(-42.97%)

9 Meters Biopharma, Inc. (NMTR) Stock Overview

Explore 9 Meters Biopharma, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

C+

Score: 59.4/100

Key Financials

Market Cap1M
P/E Ratio-0.02
EPS (TTM)$-1.69
ROE-2.07%
Fundamental Analysis

AI Price Forecasts

1 WeekN/A
1 MonthN/A
3 MonthsN/A
1 Year TargetN/A

NMTR Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of 9 Meters Biopharma, Inc. (NMTR) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of C+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of N/A.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.02 and a market capitalization of 1M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Stats data is not available for NMTRStats details for NMTR are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for NMTRAnalyst Recommendations details for NMTR are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders. The company is developing Larazotide, an 8-amino acid peptide, which is in Phase 3 clinical trial for the treatment of celiac disease, as well as in Phase IIa clinical trial for treatment of multi-system inflammatory syndrome; and Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 2 clinical trial to treat short bowel syndrome. It also develops NM-102, a small molecule peptide; NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease; NM-136, a humanized monoclonal antibody for targeted obesity disorders; and NM-004, a double-cleaved mesalamine with an immunomodulator for rare and/or orphan indications. The company is based in Raleigh, North Carolina.

CEO

Bethany Sensenig

Employees

10

Headquarters

8480 Honeycutt Road, Raleigh, NC

Founded

2016

Frequently Asked Questions

;